Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.72 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253600 | 1.00 | ABCB1 (0.72) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| SCHEMBL12896742 | 0.93 | MEN1 (0.61) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| SCHEMBL7890862 | 0.93 | MEN1 (0.61) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| SCHEMBL12897136 | 0.93 | MEN1 (0.61) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7879546 | 0.91 | MEN1 (0.60) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| SCHEMBL12896451 | 0.91 | MEN1 (0.59) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| SCHEMBL12896951 | 0.87 | MEN1 (0.56) | ABCB1TRPV6SIGMAR1MEN1KMT2A | |
| SCHEMBL4263757 | 0.86 | ABCB1 (0.69) | ABCB1TRPV6SIGMAR1CHRM2CHRM4 | |
| SCHEMBL4263760 | 0.86 | ABCB1 (0.69) | ABCB1TRPV6SIGMAR1CHRM2CHRM4 | |
| SCHEMBL12897171 | 0.83 | KDM4E (0.60) | ABCB1TRPV6MEN1KMT2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984734-B1 | SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS | UNIV BARI (IT) | 2014-05-07 | — | — | EP | claimed |
| US-20090017038-A1 | Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-01-15 | — | — | US | claimed |
| EP-1984734-A2 | SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS | Universita' degli studi di Bari (IT) | 2008-10-29 | — | — | EP | claimed |
| WO-2007077543-A2 | SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2007-07-12 | — | — | WO | claimed |
| EP-1984734-B1 | SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS | UNIV BARI (IT) | 2014-05-07 | — | — | EP | disclosed |
| US-20090017038-A1 | Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-01-15 | — | — | US | disclosed |
| EP-1984734-A2 | SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS | Universita' degli studi di Bari (IT) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007077543-A2 | SIGMA-2 RECEPTOR, METHOD OF SCREENING OF SPECIFIC LIGANDS AND USE OF THE SAME IN DIAGNOSTIC OR THERAPEUTIC METHODS | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017038-A1 | Sigma-2 Receptor, Method of Screening of Specific Ligands and Use of the Same in Diagnostic or Therapeutic Methods | SIGMAR1, TMEM97, OPRL1 | ABCB1 993/4885TRPV6 1776/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.